SLS - SELLAS Life Sciences Group, Inc.

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
2.1900
-0.0900 (-3.95%)
At close: 4:00PM EST
Stock chart is not supported by your current browser
Previous close2.2800
Open2.2500
Bid2.1000 x 1100
Ask2.2300 x 1000
Day's range2.1300 - 2.2707
52-week range2.1300 - 77.0000
Volume463,729
Avg. volume402,286
Market cap11.225M
Beta (5Y monthly)0.75
PE ratio (TTM)N/A
EPS (TTM)-23.1340
Earnings date13-Aug-2019
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est13.50
  • GlobeNewswire

    SELLAS Life Sciences Provides Regulatory Update for Nelipepimut-S (NPS) for Triple Negative Breast Cancer (TNBC) Following FDA Feedback

    NEW YORK, Feb. 14, 2020 -- SELLAS Life Sciences Group, Inc. (Nasdaq: SLS) (“SELLAS” or the “Company”), a late-stage clinical biopharmaceutical company focused on the.

  • GlobeNewswire

    SELLAS Announces Enrollment of First Patient in Phase 1 Trial of Galinpepimut-S (GPS) in Combination with Nivolumab (Opdivo®) in Patients with Malignant Pleural Mesothelioma (MPM)

    The Phase 1 open-label clinical study is being conducted by Memorial Sloan Kettering Cancer Center (MSK) and is enrolling patients with MPM who harbor relapsed or refractory disease after having received frontline, standard-of-care multimodality therapy. The principal investigator for the study is Marjorie G. Zauderer, MD, Co-Director, Mesothelioma Program and Associate Attending Physician in the Thoracic Oncology Service, Department of Medicine at MSK.

  • GlobeNewswire

    SELLAS Names Dragan Cicic, MD, as Senior Vice President, Clinical Development

    NEW YORK, Feb. 10, 2020 -- SELLAS Life Sciences Group, Inc. (Nasdaq: SLS) (“SELLAS” or the “Company”), a late-stage clinical biopharmaceutical company focused on the.

  • GlobeNewswire

    SELLAS Highlights Clinical Development Progress and Expected 2020 Milestones

    - Phase 3 Galinpepimut-S (GPS) Acute Myeloid Leukemia (AML) Study Open for Enrollment and Patient Screening Underway -              - Regulatory Feedback Regarding.

  • GlobeNewswire

    SELLAS Announces Pricing of $6.5 Million Registered Direct Offering Priced At-The-Market

    NEW YORK, Jan. 09, 2020 -- SELLAS Life Sciences Group, Inc. (Nasdaq: SLS) (“SELLAS” or the “Company”), a late-stage clinical biopharmaceutical company focused on the.

  • GlobeNewswire

    SELLAS Commences Pivotal Phase 3 REGAL Study of Galinpepimut-S (GPS) in Patients with Acute Myeloid Leukemia (AML)

    -- Study Open for Enrollment and Patient Screening Underway -- NEW YORK, Jan. 08, 2020 -- SELLAS Life Sciences Group, Inc. (Nasdaq: SLS) (“SELLAS” or the “Company”), a.

  • GlobeNewswire

    SELLAS to Present at Biotech Showcase™

    NEW YORK, Jan. 06, 2020 -- SELLAS Life Sciences Group, Inc. (Nasdaq: SLS) (“SELLAS” or the “Company”), a late-stage clinical biopharmaceutical company focused on the.

  • GlobeNewswire

    SELLAS to Present at the 12th Annual LD Micro Main Event

    NEW YORK, Dec. 04, 2019 -- SELLAS Life Sciences Group, Inc. (Nasdaq: SLS) (“SELLAS” or the “Company”), a late-stage clinical biopharmaceutical company focused on the.

  • GlobeNewswire

    SELLAS Life Sciences Provides Business Update and Reports Third Quarter 2019 Financial Results

    The Company’s planned Phase 3 registrational randomized, open-label study comparing GPS in the maintenance setting to investigators’ choice of best available treatment in adult AML patients who have achieved hematologic complete remission, with or without thrombocytopenia (CR2/CR2p), after second-line antileukemic therapy and who are deemed ineligible for or unable to undergo allogeneic stem-cell transplantation (the REGAL study) is on track to initiate by year end. Further, the Company announced that follow-up data from its Phase 1 clinical trial of GPS in combination with nivolumab to treat Wilms Tumor 1 (WT1) positive patients with ovarian cancer in second- or third-line remission continues to support the development of GPS in combination with PD-1 inhibitors.

  • GlobeNewswire

    SELLAS to Host R&D Investor Event on Galinpepimut-S (GPS) and the Next Generation of Cancer Immunotherapy

    SELLAS Life Sciences Group, Inc. (SLS) (“SELLAS” or the “Company”), a clinical-stage biopharmaceutical company focused on the development of novel cancer immunotherapies for a broad range of cancer indications, today announced that it will host a KOL Symposium for investors on Friday, November 15, 2019 from 8:15 a.m. to 10:00 a.m. ET in New York, NY. The KOL Symposium will include an overview of the Company’s ongoing clinical development programs for galinpepimut-S (GPS), with a focus on its Phase 3 trial of GPS in acute myeloid leukemia (AML), which is expected to initiate in the fourth quarter of 2019.

  • GlobeNewswire

    SELLAS Announces Reverse Stock Split

    SELLAS Life Sciences Group, Inc. (SLS) (“SELLAS” or the “Company”), a clinical-stage biopharmaceutical company focused on the development of novel cancer immunotherapies for a broad range of cancer indications, today announced that it filed a certificate of amendment to its amended and restated certificate of incorporation with the Secretary of State of the State of Delaware to effect a 1-for-50 reverse stock split of its common stock. The shares underlying the Company’s outstanding options and warrants will also be adjusted accordingly. The reverse split will take effect at 5:00 pm Eastern Time on November 7, 2019 and the Company’s common stock will open for trading on The Nasdaq Capital Market on November 8, 2019 on a post-split basis.

  • GlobeNewswire

    SELLAS Life Sciences Provides Business Update and Reports Second Quarter 2019 Financial Results

    “In recent months, we have made clinical advancements across our pipeline of novel cancer peptide vaccines, particularly with our program for galinpepimut-S (GPS) in combination with anti-PD-1 therapies where we believe these treatments may be synergistic, ,” said Angelos Stergiou, MD, ScD h.c., President and Chief Executive Officer of SELLAS. “As we look forward, we anticipate the following key milestones during the remainder of the year: (i) initiation of our Phase 3 registrational study of GPS in patients with acute myeloid leukemia (AML), (ii) first patient dosed in the investigator-sponsored study of GPS in combination with nivolumab in patients with malignant pleural mesothelioma (MPM), and (iii) initial clinical data from our Phase 2 trial of nelipepimut-S (NPS) in ductal carcinoma in situ (DCIS).

  • GlobeNewswire

    SELLAS Announces Completion of Enrollment in Randomized Phase 2 VADIS Trial of Nelipepimut-S (NPS) in Women with Ductal Carcinoma In Situ (DCIS) of the Breast

    SELLAS Life Sciences Group, Inc. (SLS) (“SELLAS” or the “Company”), a clinical-stage biopharmaceutical company focused on the development of novel cancer immunotherapies for a broad range of cancer indications, today announced completion of enrollment in a Phase 2 randomized investigator-sponsored trial (IST) of nelipepimut-S (NPS) in combination with granulocyte-macrophage colony-stimulating factor (GM-CSF) in women with ductal carcinoma in situ (DCIS) of the breast who are HLA-A2+ or A3+ positive, express HER2 at IHC 1+, 2+, or 3+ levels, and are pre- or post-menopausal. “We are pleased to announce completion of enrollment in the Phase 2 VADIS trial, an important milestone for our NPS clinical program.

  • GlobeNewswire

    SELLAS Advances Galinpepimut-S (GPS) in Combination with KEYTRUDA® (pembrolizumab) Program with Dosing of First Patient in Phase 1/2 Basket Study

    SELLAS Life Sciences Group, Inc. (SLS) (“SELLAS” or the “Company”), a clinical-stage biopharmaceutical company focused on the development of novel cancer immunotherapies for a broad range of cancer indications, today announced the dosing of the first patient in its Phase 1/2 open-label study of GPS in combination with Merck’s anti-PD-1 therapy KEYTRUDA® (pembrolizumab), in patients with selected WT1-positive advanced cancers, including both solid tumors and hematologic malignances. “This is an important milestone as this study allows us to potentially enhance our safety and activity profile of GPS in combination with anti-PD-1 therapies, particularly in combination with KEYTRUDA® in multiple malignances, following intriguing initial combination clinical data with OPDIVO®,” said Angelos M. Stergiou, M.D., ScD h.c., President and Chief Executive Officer of SELLAS.

  • Investors Who Bought SELLAS Life Sciences Group (NASDAQ:SLS) Shares A Year Ago Are Now Down 97%
    Simply Wall St.

    Investors Who Bought SELLAS Life Sciences Group (NASDAQ:SLS) Shares A Year Ago Are Now Down 97%

    It's not a secret that every investor will make bad investments, from time to time. But serious investors should think...

  • GlobeNewswire

    SELLAS Life Sciences Announces Closing of $15 Million Public Offering

    SELLAS Life Sciences Group, Inc. (SLS) (“SELLAS” or the “Company”), a late-stage biopharmaceutical company focused on the development of novel cancer immunotherapeutics for a broad range of indications, today announced the closing of its previously announced underwritten public offering of (i) 26,367,200 shares of common stock together with common stock warrants (the “common warrants”) to purchase 26,367,200 shares of common stock and (ii) 73,632,800 pre-funded warrants, with each pre-funded warrant exercisable for one share of common stock, together with common warrants to purchase 73,632,800 shares of common stock. At closing, SELLAS received aggregate net proceeds from the offering of approximately $13.5 million, after deducting underwriting discounts and commissions and estimated offering expenses.

  • GlobeNewswire

    SELLAS Life Sciences Announces Pricing of $15 Million Public Offering

    SELLAS Life Sciences Group, Inc. (SLS) (“SELLAS” or the “Company”), a clinical stage biopharmaceutical company focused on the development of novel cancer immunotherapeutics for a broad range of cancer indications, today announced the pricing of an underwritten public offering of (i) 26,367,200 shares of common stock together with common stock warrants (the “common warrants”) to purchase 26,367,200 shares of common stock and (ii) 73,632,800 pre-funded warrants, with each pre-funded warrant exercisable for one share of common stock, together with common warrants to purchase 73,632,800 shares of common stock. The shares of common stock (or pre-funded warrants, as applicable) and accompanying common warrants are being sold together at a combined public offering price of $0.15 per share.

  • GlobeNewswire

    SELLAS Announces Immune Response Data in Triple Negative Breast Cancer Patients from Phase 2b Study of Nelipepimut-S (NPS) Plus Trastuzumab Presented at ASCO 2019

    NPS-Specific Cytotoxic T-Lymphocyte Mean Frequencies Increased by 2.86-fold Compared to Baseline at 30 months Notable Correlation Between Progressive Increase of NPS-Specific.

  • GlobeNewswire

    SELLAS Life Sciences Provides Business Update and Reports First Quarter 2019 Financial Results

    “Throughout 2019, as we have been progressing the review of strategic alternatives, we also have been continuing to advance our novel cancer immunotherapy clinical pipeline and are excited to be presenting data on one of our clinical candidates, nelipepimut-S (NPS), at the upcoming American Society of Clinical Oncology (ASCO) Annual Meeting,” said Angelos Stergiou, MD, ScD h.c., President and Chief Executive Officer of SELLAS.

  • GlobeNewswire

    SELLAS Life Sciences Group and World-Renowned Cancer Center to Study Galinpepimut-S (GPS) in Combination with Nivolumab in Patients with Malignant Pleural Mesothelioma (MPM)

    SELLAS Life Sciences Group, Inc. (SLS) (“SELLAS” or the “Company”), a clinical-stage biopharmaceutical company focused on the development of novel cancer immunotherapies for a broad range of cancer indications, today announced agreement with Memorial Sloan Kettering Cancer Center (MSK) for the conduct of an investigator-sponsored clinical trial of SELLAS' Wilms tumor-1 (WT1)-targeting peptide immunotherapeutic agent, galinpepimut-S (GPS), in combination with Bristol-Myers Squibb’s anti-PD-1 therapy, nivolumab, in patients with malignant pleural mesothelioma (MPM). The Phase 1 open-label clinical study will enroll patients with MPM who harbor relapsed or refractory disease after having received frontline standard of care multimodality therapy with study drug provided by both SELLAS and Bristol-Myers Squibb.

  • GlobeNewswire

    SELLAS Life Sciences Reports 2018 Financial Results and Provides Business Update

    SELLAS Life Sciences Group, Inc. (SLS) (“SELLAS” or the “Company”), a clinical-stage biopharmaceutical company focused on the development of novel cancer immunotherapies for a broad range of cancer indications, today reported financial results for the year ended December 31, 2018 and provided a business update. “In February, we initiated a review of a wide range of strategic alternatives to maximize shareholder value, such as a sale of the Company, a merger, or a strategic investment or financing,” stated Dr. Angelos M. Stergiou, M.D., ScD h.c., President and Chief Executive Officer of SELLAS. In February 2019, the Company announced that its Board of Directors is conducting a review of strategic options focusing on maximizing shareholder value.

  • GlobeNewswire

    SELLAS Life Sciences Announces Presentation of Final Data Analysis from Phase 2b Study of Nelipepimut-S Plus Trastuzumab at the 2019 ASCO-SITC Clinical Immuno-Oncology Meeting

    NEW YORK, March 04, 2019 -- SELLAS Life Sciences Group, Inc. (Nasdaq: SLS) (“SELLAS” or the “Company”), a clinical-stage biopharmaceutical company focused on the development of.

  • GlobeNewswire

    SELLAS Life Sciences Announces Review of Strategic Alternatives

    SELLAS Life Sciences Group, Inc. (SLS) (“SELLAS” or the “Company”), a clinical-stage biopharmaceutical company focused on the development of novel cancer immunotherapies for a broad range of cancer indications, today announced that its Board of Directors is conducting a review of strategic options focusing on maximizing shareholder value. The Company has engaged Cantor Fitzgerald & Co. to act as its strategic and financial advisor for this process.